المؤلفون: João Martins Gama, Rui Caetano Oliveira, José Casanova

المصدر: Acta Médica Portuguesa (2024)

مصطلحات موضوعية: Denosumab/therapeutic use, Fibula, Giant Cell Tumor of Bone/drug therapy, Giant Cell Tumor of Bone/pathology, Medicine, Medicine (General), R5-920

الوصف: N/a.

وصف الملف: electronic resource

العلاقة: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/21067Test; https://doaj.org/toc/0870-399XTest; https://doaj.org/toc/1646-0758Test

الوصول الحر: https://doaj.org/article/f25b2d2fd108401fb49f79916aebb837Test

المؤلفون: Shinji Tsukamoto, Andreas F. Mavrogenis, Tomoya Masunaga, Kanya Honoki, Hiromasa Fujii, Akira Kido, Yasuhito Tanaka, Costantino Errani

المصدر: Current Oncology, Vol 31, Iss 4, Pp 2112-2132 (2024)

مصطلحات موضوعية: giant cell tumor of bone, extremity, pelvis, sacrum, spine, denosumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Curettage is recommended for the treatment of Campanacci stages 1–2 giant cell tumor of bone (GCTB) in the extremities, pelvis, sacrum, and spine, without preoperative denosumab treatment. In the distal femur, bone chips and plate fixation are utilized to reduce damage to the subchondral bone and prevent pathological fracture, respectively. For local recurrence, re-curettage may be utilized when feasible. En bloc resection is an option for very aggressive Campanacci stage 3 GCTB in the extremities, pelvis, sacrum, and spine, combined with 1–3 doses of preoperative denosumab treatment. Denosumab monotherapy once every 3 months is currently the standard strategy for inoperable patients and those with metastatic GCTB. However, in case of tumor growth, a possible malignant transformation should be considered. Zoledronic acid appears to be as effective as denosumab; nevertheless, it is a more cost-effective option. Therefore, zoledronic acid may be an alternative treatment option, particularly in developing countries. Surgery is the mainstay treatment for malignant GCTB.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/31/4/157Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/f62b6196431744b2b54403251951f64fTest

المؤلفون: Lukuan Cui, Yang Sun, Tao Jin, Daoyang Fan, Weifeng Liu

المصدر: Discover Oncology, Vol 15, Iss 1, Pp 1-11 (2024)

مصطلحات موضوعية: Giant cell tumor of bone, Soft tissue, Recurrence, Ultrasonography, Risk factor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Soft tissue recurrence of giant cell tumor of bone (GCTB) is rare. This study aims to provide its prevalence, recurrent locations, risk factors, effective detection methods and a modified classification for this recurrence. Methods Patients with soft tissue recurrence after primary surgery for GCTB were screened from January 2003 to December 2022. General data, recurrence frequency, types according to an original classification (type-I: peripheral ossification; type-II: central ossification; type-III: without ossification), a modified classification with more detailed subtypes (type I-1: ≤ 1/2 peripheral ossification; type I-2: ≥ 1/2 peripheral ossification; type II-1: ≤ 1/2 central ossification; type II-2: ≥ 1/2 central ossification; type III: without ossification), locations, detection methods such as ultrasonography, X-ray, CT or MRI, Musculoskeletal Tumor Society (MSTS) scores were recorded. Multivariate regression analysis was conducted to identify risk factors for recurrence frequency. Results A total of 558 recurrent cases were identified from 2009 patients with GCTB. Among them, 32 were soft tissue recurrence. The total recurrence rate was 27.78% (558/2009). Soft tissue recurrence rate was 5.73% among 558 recurrent cases, and 1.59% among 2009 GCTB patients, respectively. After excluding one patient lost to follow-up, 10 males and 21 females with the mean age of 28.52 ± 9.93 (16–57) years were included. The definitive diagnosis of all recurrences was confirmed by postoperative pathology. The interval from primary surgery to the first recurrence was 23.23 ± 26.12 (2–27) months. Eight recurrences occurred from primary GCTB located at distal radius, followed by distal femur (6 cases). Recurrence occurred twice in 12 patients and 3 times in 7 patients. Twenty-seven recurrences were firstly detected by ultrasonography, followed by CT or X-ray (10 cases in each). Types at the first recurrence were 5 cases in type-I, 8 in type-II and 18 in type-III. According to the modified classification, 3 patients in type I-1, 2 in type I-2, 1 in type II-1, 7 in type II-2, and 18 in type III. The mean MSTS score was 26.62 ± 4.21 (14—30). Neither Campanacci grade nor recurrence type, modified classification and other characters, were identified as risk factors. Conclusions Soft tissue recurrence of GCTB may recur for more than once and distal radius was the most common location of primary GCTB that would suffer a soft tissue recurrence. Ultrasonography was a useful method to detect the recurrence. Since no risk factors were discovered, a careful follow-up with ultrasonography was recommended.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2730-6011Test

الوصول الحر: https://doaj.org/article/cedc692542914e4d947d3cf0eb7809e2Test

المؤلفون: Adisak Wongkajornsilpa, Rapin Phimolsarnti, Chandhanarat Chandhanayingyong, Saranatra Waikakul, Pojchong Chotiyarnwong

المصدر: Siriraj Medical Journal, Vol 76, Iss 6 (2024)

مصطلحات موضوعية: Thermoablation, pH, giant cell tumor of bone, in vitro, Medicine

الوصف: Objective: To evaluate the effect of pH on the apoptosis and necrosis rate of giant cell tumor of bone (GCTB) cells during thermoablation. Materials and Methods: GCTB tissues were collected from 15 patients. Cells were incubated at 25 ºC , 37 ºC, 45 ºC, and 50 ºC, with the variation of the pH at 4.7, 5.6, 6.5, 7.4, 8.3, and 9.2 for 20 minutes (in triplicate for each condition). The effect of thermoablation and pH variation on GCTB cells death was evaluated by staining with Annexin V-FITC and propidium iodide solution after 3 days of incubation. The fluorescence intensity was evaluated by flow cytometry to evaluate the percentage of tumor cells death. Results: Thermoablation alone increased the percentage of tumor cells death. However, when combined with an increase in pH, the percentage of GCTB cells death increased more. Conversely, lowering the pH did not increase the tumor cells death compared with thermoablation treatment alone, while changing the pH alone had only a low effect on increasing the percentage of GCTB cells death. Conclusion: Thermoablation the temperature between 37 ºC and 45 ºC plus a pH level slightly higher than physiologic pH (between 7.4 and 8.3) for 20 minutes increased GCTB cell death. However, determining the optimum condition to kill tumor cells while causing minimal harm to normal cells requires more study.

وصف الملف: electronic resource

العلاقة: https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/266988Test; https://doaj.org/toc/2228-8082Test

الوصول الحر: https://doaj.org/article/53cbea887d154c2aa3260ef2fd5904e2Test

المؤلفون: Niket Todi, David M. Hiltzik, Drew D. Moore

المصدر: Heliyon, Vol 10, Iss 10, Pp e30890- (2024)

مصطلحات موضوعية: Giant cell tumor of bone, Secondary osteoarthritis, Musculoskeletal oncology, Total knee arthroplasty, Science (General), Q1-390, Social sciences (General), H1-99

الوصف: Giant cell tumor of bone is a commonly encountered aggressive epiphyseal bone tumor, most often treated surgically. The natural history and presentation are classically described but the histopathology is poorly understood. Intralesional curettage is the mainstay of treatment, but there is significant variation in the use of adjuvant and cavity filling modalities. No gold standard has been agreed upon for treatment, and a variety of techniques are currently in use. Given its location, secondary osteoarthritis is a known long-term complication. This review examines the natural history of giant cell tumors, treatment options and complications, and subsequent development of osteoarthritis. Arthroplasty is usually indicated for secondary osteoarthritis although data is limited on its efficacy. Further directions will likely center on improved pharmacological treatments as well as improved arthroplasty techniques.

وصف الملف: electronic resource

العلاقة: http://www.sciencedirect.com/science/article/pii/S2405844024069214Test; https://doaj.org/toc/2405-8440Test

الوصول الحر: https://doaj.org/article/1626d0dbea8b4f60b5e320f0cee55a48Test

المؤلفون: Ao Leng, Minglei Yang, Haitao Sun, Zeyu Dai, Zhi Zhu, Wei Wan, Jianru Xiao

المصدر: Orthopaedic Surgery, Vol 16, Iss 1, Pp 78-85 (2024)

مصطلحات موضوعية: Denosumab, En bloc spondylectomy, Giant cell tumor of bone, Spinal neoplasms, Orthopedic surgery, RD701-811

الوصف: Objective Recurrent giant cell tumor (RGCT) of the spine represents a clinical challenge for surgeons, and the treatment strategy remains controversial. This study aims to describe the long‐term follow‐up outcomes and compare the efficacy of en bloc spondylectomy versus piecemeal spondylectomy in treating RGCT of the thoracolumbar spine. Methods A total of 32 patients with RGCT of the thoracolumbar spine treated from June 2012 to June 2019 were retrospectively reviewed. A total of 15 patients received total en bloc spondylectomy (TES) with wide or marginal margin while 17 patients received total piecemeal spondylectomy (TPS) with intralesional margin. Postoperative Eastern Cooperative Oncology Group Performance Score (ECOG‐PS), Frankel classification and recurrence‐free survival (RFS) were evaluated after surgery. Survival curves were estimated by the Kaplan–Meier method and differences were analyzed with the log‐rank test. Multivariate analysis was performed with Cox regression to identify the independent prognostic factors affecting RFS. Results During a median follow‐up of 41.9 ± 17.5 months, all patients with compromised neurologic functions exhibit significant improvement, with the mean ECOG‐PS decreasing from 1.5 ± 1.3 to 0.13 ± 0.3 (p

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1757-7853Test; https://doaj.org/toc/1757-7861Test

الوصول الحر: https://doaj.org/article/34145dcb05f64fb4878413f882474959Test

المؤلفون: Ricardo Gehrke Becker, Carlos Roberto Galia, Julie Francine Cerutti Santos Pestilho, Bruno Pereira Antunes, André Mathias Baptista, Alex Guedes

المصدر: Acta Ortopédica Brasileira, Vol 32, Iss 1 (2024)

مصطلحات موضوعية: Bone Neoplasms, Giant Cell Tumor of Bone, Curettage, Recurrence, Medicine, Orthopedic surgery, RD701-811

الوصف: ABSTRACT Introduction: Giant cell tumor of bone (GCTB) mainly affects young adults’ long bone epiphyses, threatening bone strength and joint function. Surgery is the primary treatment, although post-surgery recurrence is significant. This study analyzes patient profiles, treatments, and outcomes for GCTB in Brazil. Methods: We retrospectively assessed local recurrence, metastasis, and treatment approaches in 643 GCTB patients across 16 Brazilian centers (1989-2021), considering regional differences. Results: 5.1% (n=33) developed pulmonary metastases, 14.3% (n=92) had pathological fractures, and the local recurrence rate was 18.2% (n=114). Higher rates of pulmonary metastases (12.1%) and advanced tumors (Campanacci III, 88.9%) were noted in lower-income North and Northeast regions. The North also had more pathological fractures (33.3%), extensive resections (61.1%), and amputations (27.8%). These regions faced longer surgical delays (36-39 days) than the South and Southeast (27-33 days). Conclusions: Our findings corroborate international data, underscoring regional disparities in Brazil that may lead to worse outcomes in disadvantaged areas. This highlights the need for improved orthopedic oncology care in Brazil’s economically and structurally challenged regions. Level of Evidence III; Retrospective Cohort.

وصف الملف: electronic resource

العلاقة: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-78522024000100800&tlng=enTest; https://doaj.org/toc/1413-7852Test

الوصول الحر: https://doaj.org/article/cce8f091f6dd43efbb67f8a3172283deTest

المؤلفون: Lenian Zhou, Juan Tang, Longxiang Shen, Zhichang Zhang, Ting Yuan

المصدر: Journal of Orthopaedic Surgery and Research, Vol 18, Iss 1, Pp 1-9 (2023)

مصطلحات موضوعية: Giant cell tumor of bone, Distal ulna tumors, Wrist, Darrach procedure, Sauvé–Kapandji procedure, Extensor carpi ulnaris tenodesis, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935

الوصف: Abstract Objective The wrist is the second most commonly involved location for GCTB, while distal ulna is a relatively rare location and limited evidence exists on which surgical approaches and reconstruction techniques are optimal. We carried out a multicenter retrospective study to evaluate the recurrence rate of distal ulna GCTB and the long-term functional outcomes of different surgery options. Methods All 28 patients received surgical treatment for distal ulna GCTB in one of three tertiary bone tumor centers between May 2007 and January 2021 with a minimum two-year follow-up. Surgical options included intralesional curettage or en bloc resection (one of 3 types). Functional outcomes were assessed by the MSTS score, the QuickDASH instrument, MWS, and MHQ according to the latest treatment. Results Overall recurrence rate was 14.2%. The curettage group (N = 7) had a significantly higher recurrence rate compared to en bloc resection (N = 21) (42.9% vs 4.8%) (mean follow-up: 88.8 mo). Seven patients received the Darrach procedure, 5 received the original Sauvé–Kapandji procedure, and 9 received the modified Sauvé–Kapandji procedure with extensor carpi ulnaris (ECU) tenodesis. Of the 4 patients having a recurrence, 1 received the Darrach EBR, 2 received the modified Sauvé–Kapandji procedure, and 1 received resection for soft tissue recurrence. Only MWS and esthetics in the MHQ scores were different (curettage, Darrach, Sauvé–Kapandji, and Sauvé–Kapandji with ECU tenodesis [MWS: 96.5 ± 1.3 vs 91.5 ± 4.7 vs 90.8 ± 2.8 vs 91.5 ± 3.6; esthetics in MHQ: 98.5 ± 3.1 vs 89.9 ± 4.7 vs 93.8 ± 4.4 vs 92.6 ± 3.8], respectively). Conclusions En bloc resection for distal ulna GCTB had a significantly lower recurrence rate compared with curettage and achieved favorable functional outcome scores. Given the higher recurrence rate after curettage, patients should be well informed of the potential benefits and risks of selecting the distal radioulnar joint-preserving procedure. Moreover, reconstructions after tumor resection of the ulna head do not appear to be necessary.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1749-799XTest

الوصول الحر: https://doaj.org/article/8cea6a09976b4922b0d0652cd446949aTest

المؤلفون: Sumedh Kumar, Brajesh Nandan, Ravi Chauhan, Manish Dhawan, Siddharth Agrawal, Sijal Rivi

المصدر: Revista Brasileira de Ortopedia, Vol 58, Iss 2, Pp 211-221 (2023)

مصطلحات موضوعية: argon plasma coagulation, giant cell tumor of bone, bone neoplasms, chemoradiotherapy, adjuvant, orthopedics, Medicine, Orthopedic surgery, RD701-811

الوصف: Abstract Objective Extended curettage with adjuvants of giant cell tumors of bone is associated with a lower rate of recurrence of the tumor while preserving the adjacent joint. The present study was conducted to estimate the recurrence rate and functional outcome after using argon beam as an adjuvant for extended curettage. Methods We selected 50 patients with giant cell tumors, meeting all the inclusion criteria, who underwent extended curettage using high speed burr and argon beam photocoagulation between July 2016 to January 2019. On their follow-up visit, they were assessed for any complaints of pain and signs like tenderness, locally raised temperature, and decreased range of motion of the adjacent joint. Radiologically, the patients were assessed for any increased lucency around the cement mantle and uptake of the subarticular graft. Musculoskeletal Tumor Society Score (MSTS) was administered to the patients, and range of motion of the adjacent joint was compared with the contralateral joint. Results Recurrence was found in 4 patients, that is, an 8% recurrence rate. Twenty-six out of 28 patients with a tumor in the lower limb had a grade-5 weight bearing status 6 months from the surgery, and their range of motion was comparable to contralateral healthy joint with an average MSTS score of 27 (18–30). Conclusion Extended curettage of giant cell tumors using argon beam coagulation is associated with low recurrence rates of the tumor and is an effective modality in the treatment of these tumors besides having a functional outcome comparable to the healthy limb.

وصف الملف: electronic resource

العلاقة: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-36162023000200211&tlng=enTest; http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-36162023000200211&tlng=ptTest; https://doaj.org/toc/1982-4378Test

الوصول الحر: https://doaj.org/article/38fc9c1337274220aa4977de475027feTest

المؤلفون: Jun Nishio, Shizuhide Nakayama, Kaori Koga, Mikiko Aoki

المصدر: Journal of Clinical Medicine, Vol 13, Iss 10, p 2870 (2024)

مصطلحات موضوعية: giant cell tumor of soft tissue, giant cell tumor of bone, diagnosis, pathogenesis, treatment, tenosynovial giant cell tumor, Medicine

الوصف: Giant cell tumor of soft tissue (GCTST) is a locally aggressive mesenchymal neoplasm of intermediate malignancy that predominantly occurs in the superficial soft tissue of the extremities. It is histologically similar to a giant cell tumor of bone (GCTB) and shows a mixture of round to oval mononuclear cells and osteoclast-like multinucleated giant cells. Currently, immunohistochemistry plays a very limited role in the diagnosis of GCTST. Primary or secondary malignant GCTST has recently been described and tumors exhibiting high-grade histological features demonstrate higher rates of distant metastasis. GCTST lacks the H3-3A gene mutations that are identified in the vast majority of GCTBs, suggesting a different pathogenesis. Surgery is the standard treatment for localized GCTST. Incomplete surgical resection is usually followed by local recurrence. Radiation therapy may be considered when the close proximity of critical structures prevents microscopically negative surgical margins. The systemic treatment options for advanced or metastatic disease are very limited. This review provides an updated overview of the clinicoradiological features, pathogenesis, histopathology, and treatment for GCTST. In addition, we will discuss the differential diagnosis of this peculiar neoplasm.

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2077-0383/13/10/2870Test; https://doaj.org/toc/2077-0383Test

الوصول الحر: https://doaj.org/article/207a2bb9e6264f639ae09dba8afffeabTest